{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-013841","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.874445+00:00","generated_at":"2026-05-27T08:18:52.614765+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lantheus to acquire Evergreen Theragnostics for $250M upfront plus up to $752.5M in milestones","bullets":["Upfront cash consideration $250M; potential milestone payments up to $752.5M based on OCTEVY and pipeline products.","Evergreen adds radiopharmaceutical CDMO manufacturing infrastructure and registrational-stage NET diagnostic OCTEVY.","Transaction expected to close in second half of 2025, subject to regulatory clearances and customary conditions.","Lantheus reaffirms FY2024 revenue guidance of $1.51B-$1.52B and adjusted EPS of $6.65-$6.70."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-013841","json":"https://secwatch.observer/filing/0001193125-25-013841.json","markdown":"https://secwatch.observer/filing/0001193125-25-013841.md","text":"https://secwatch.observer/filing/0001193125-25-013841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525013841/0001193125-25-013841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525013841/d925405d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:18:52.614765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}